Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Nov 10, 4:55 PMEnvista prices $430 million of 6.250% senior notes due 2033, with proceeds earmarked to repay its U.S. dollar term loan A facility and for general corporate purposes.
Index
RUI
Market Cap
4.06B
Enterprise Value
4.49B
Income
633.60M
Sales
2.88B
Book/sh
19.27
Cash/sh
7.23
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
12000
IPO
Sep 18, 2019
P/E
6.54
Forward P/E
15.13
PEG
1.00
P/S
1.41
P/B
1.31
P/C
3.50
P/FCF
16.78
EV/EBITDA
10.11
EV/Sales
1.56
Quick Ratio
2.10
Current Ratio
2.45
Debt/Eq
0.51
LT Debt/Eq
0.50
Option/Short
Yes / Yes
EPS (ttm)
3.87
EPS next Y
1.67
EPS next Q
0.40
EPS this Y
31.11%
EPS next Y
7.24%
EPS next 5Y
15.14%
EPS past 3/5Y
-40.82% 6.49%
Sales past 3/5Y
1.91% 7.11%
EPS Y/Y TTM
4511.50%
Sales Y/Y TTM
9.78%
EPS Q/Q
1805.48%
Sales Q/Q
3.22%
Insider Own
2.36%
Insider Trans
-0.21%
Inst Own
118.79%
Inst Trans
6.76%
ROA
11.26%
ROE
20.52%
ROIC
13.66%
Gross Margin
56.46%
Oper. Margin
11.55%
Profit Margin
22.01%
SMA20
4.20%
SMA50
4.15%
SMA200
-1.79%
Trades
Shs Outstand
160.30M
Shs Float
156.55M
52W High
30.42 -16.77%
52W Low
18.77 34.90%
Volatility
5.38% 3.93%
ATR (14)
1.02
RSI (14)
54.81
Beta
0.94
Rel Volume
0.00
Avg Volume
2.90M
Volume
0
Perf Week
-6.88%
Perf Month
11.79%
Perf Quarter
-9.83%
Perf Half Y
5.85%
Perf YTD
16.63%
Perf Year
25.28%
Perf 3Y
17.39%
Perf 5Y
-40.94%
Perf 10Y
-
Prev Close
25.32
Price
25.32
Change %
0.00%
Consensus
Buy
Avg. Price Target
$28.92
Implied Upside
+14.2%
Analysts15incl. previous ratings
Rating Distribution3 Buy · 10 Hold · 2 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 15, 2026Downgrade
RRobert W. Baird
Outperform → Neutral$26+2.7%
Sep 03, 2026Upgrade
JPM logoJJP Morgan
Neutral → Overweight$32+26.4%
Jul 09, 2026Initiated
BMO logoBBMO Capital Markets
Market Perform$27+6.6%
Apr 15, 2026Initiated
C logoCCitigroup
Neutral$29+14.5%
Feb 06, 2026Upgrade
LLeerink Partners
Market Perform → Outperform$35+38.2%
Dec 09, 2025Initiated
BCS logoBBarclays
Overweight$24-5.2%
May 27, 2025Upgrade
RRobert W. Baird
Neutral → Outperform$23-9.2%
Dec 04, 2024Initiated
MFG logoMMizuho
Underperform$20-21.0%
Oct 31, 2024Upgrade
LLeerink Partners
Underperform → Market Perform$16 → $23-9.2%
Oct 08, 2024Initiated
WFC logoWWells Fargo
Equal Weight$20-21.0%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Reis MischaSVP, Strategy & Bus. Dev.Aug 20 '26Sale27.508,000220,00027,321Aug 24 04:25 PM
Reis MischaOfficerAug 20 '26Proposed Sale27.508,000220,000Aug 20 01:28 PM
Reis MischaSVP, Strategy & Bus. Dev.Feb 10 '26Option Exercise17.259,675166,91638,016Feb 11 05:15 PM
Reis MischaSVP, Strategy & Bus. Dev.Feb 10 '26Sale30.009,675290,25032,382Feb 11 05:15 PM
Reis MischaOfficerFeb 10 '26Proposed Sale30.009,675290,250Feb 10 12:40 PM
Envista Holdings Corp. engages in the manufacturing and marketing of dental products, diagnostics, treatment, and trading. It offers dental consumables, equipment, and services to dental professionals. It operates through the Specialty Products and Technologies, and Equipment and Consumables segments. The Specialty Products and Technologies segment develops, manufactures, and markets dental implant systems, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment and Consumables segments refers to developing, manufacturing, and marketing dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization and magnification systems, handpieces and associated consumables, treatment units and other dental practice equipment, endodontic systems, and related consumables, restorative materials and instruments, rotary burs, impression materials, bonding agents and cements, and infection prevention products. The company was founded on August 29, 2018 and is headquartered in Brea, CA.
PresidentMr. Paul A. Keel
Senior VP & CFOMr. Eric D. Hammes
Senior VPMr. Mark E. Nance J.D.
Senior VP & President of DiagnosticsMr. Robert Befidi Jr.
Senior VP & President of OrthodonticsMs. Veronica Acurio